Abstract

Case Report

Late Extensive Regional Recurrence of Paratesticular Dedifferentiated Liposarcoma 10 Years after Orchiectomy: A Case Report

Mohammed Amine Elafari*, Mamad Ayoub, Mohammed Amine Bibat, Amine Slaoui, Tariq Karmouni, Abdelatif Koutani and Khalid Elkhader

Published: 01 April, 2026 | Volume 10 - Issue 1 | Pages: 006-010

Background: Paratesticular liposarcoma is a rare entity, with dedifferentiated liposarcoma (DDLPS) representing the most aggressive subtype. Late recurrences with unusual patterns of spread have been documented but remain poorly characterized.
Case presentation: We report a case of a 68-year-old male with a 10-year recurrence of paratesticular DDLPS following right orchiectomy. The patient initially underwent resection of a 5×4×4.5 cm paratesticular mass in 2015, with histopathology confirming DDLPS and negative distal spermatic cord margins. After loss to follow-up, he presented in 2026 with extensive regional recurrence involving bilateral pubic soft tissues, abdominal wall musculature, and right external iliac lymphadenopathy. Biopsy confirmed recurrent DDLPS with Mouse double minute 2 homolog (MDM2) positivity. Given the multi-site infiltrative nature and muscle involvement, the multidisciplinary team recommended neoadjuvant chemotherapy with ifosfamide and doxorubicin before consideration of surgical resection.
Conclusion: This case illustrates the propensity for late regional recurrence in paratesticular DDLPS and highlights the unusual pattern of spread along anatomic pathways, including the abdominal wall and inguinal region. The case underscores the importance of long-term surveillance, aggressive initial surgical margins, and multidisciplinary management in this rare malignancy.

Read Full Article HTML DOI: Cite this Article Read Full Article PDF

Keywords:

Paratesticular liposarcoma; Dedifferentiated liposarcoma; Late recurrence; MDM2; Neoadjuvant chemotherapy

References

  1. Khandekar MJ, Raut CP, Hornick JL, Wang Q, Alexander BM, Baldini EH. Paratesticular liposarcoma: unusual patterns of recurrence and importance of margins. Ann Surg Oncol. 2013;20(7):2148-2155. Available from: https://doi.org/10.1245/s10434-013-2963-0
  2. Kamitani R, Matsumoto K, Takeda T, Mizuno R, Oya M. Optimal treatment strategy for paratesticular liposarcoma: retrospective analysis of 265 reported cases. Int J Clin Oncol. 2020;25(12):2099-2106. Available from: https://doi.org/10.1007/s10147-020-01753-3
  3. Obeidat A. Predictors of survival in dedifferentiated liposarcoma: a population-based analysis of the SEER database. Medicine (Baltimore). 2026;105(9):e47738. Available from: https://doi.org/10.1097/md.0000000000047738
  4. Lee ATJ, Thway K, Huang PH, Jones RL. Clinical and molecular spectrum of liposarcoma. J Clin Oncol. 2018;36(2):151-159. Available from: https://doi.org/10.1200/jco.2017.74.9598
  5. Thway K. Well-differentiated liposarcoma and dedifferentiated liposarcoma: an updated review. Semin Diagn Pathol. 2019;36(2):112-121. Available from: https://doi.org/10.1053/j.semdp.2019.02.006
  6. Nishio J, Nakayama S, Nabeshima K, Yamamoto T. Biology and management of dedifferentiated liposarcoma: state of the art and perspectives. J Clin Med. 2021;10(15):3230. Available from: https://doi.org/10.3390/jcm10153230
  7. Haddox CL, Hornick JL, Roland CL, Baldini EH, Keedy VL, Riedel RF. Diagnosis and management of dedifferentiated liposarcoma: a multidisciplinary position statement. Cancer Treat Rev. 2024;131:102846. Available from: https://doi.org/10.1016/j.ctrv.2024.102846
  8. Li J, Wang J, Han H, Tian L, Yin H. Case report: two cases of primary paratesticular liposarcoma. Front Oncol. 2022;12:1040458. Available from: https://doi.org/10.3389/fonc.2022.1040458
  9. Reback T, Pang KH, Haider A, Freeman A, Shankar A, Alnajjar HM, et al. Paratesticular sarcoma: analysis of oncological outcomes and prognostic factors. Clin Genitourin Cancer. 2025;23(3):102331. Available from: https://doi.org/10.1016/j.clgc.2025.102331
  10. Montgomery E, Fisher C. Paratesticular liposarcoma: a clinicopathologic study. Am J Surg Pathol. 2003;27(1):40-47. Available from: https://doi.org/10.1097/00000478-200301000-00005
  11. Zhao J, Du W, Tao X, Li A, Li Y, Zhang S. Survival and prognostic factors among different types of liposarcomas based on the SEER database. Sci Rep. 2025;15(1):1790. Available from: https://doi.org/10.1038/s41598-025-85937-9
  12. Casier J, Timmermans I, Laenen A, Hompes D, Douchy T, Sciot R, et al. Clinical course and prognostic factors of patients with dedifferentiated liposarcoma: a retrospective analysis. BMC Cancer. 2025;25(1):517. Available from: https://doi.org/10.1186/s12885-025-13813-w
  13. Mori T, Yamada Y, Kinoshita I, Kohashi K, Yamamoto H, Ito Y, et al. Clinicopathological and histopathological review of dedifferentiated liposarcoma: a comprehensive study of 123 primary tumours. Histopathology. 2022;80(3):538-557. Available from: https://doi.org/10.1111/his.14588
  14. Thway K, Jones RL, Noujaim J, Zaidi S, Miah AB, Fisher C. Dedifferentiated liposarcoma: updates on morphology, genetics, and therapeutic strategies. Adv Anat Pathol. 2016;23(1):30-40. Available from: https://doi.org/10.1097/pap.0000000000000101
  15. Stacchiotti S, Van der Graaf WTA, Sanfilippo RG, Marreaud SI, Van Houdt WJ, Judson IR, et al. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Cancer. 2022;128(15):2932-2938. Available from: https://doi.org/10.1002/cncr.34264
  16. National Comprehensive Cancer Network (NCCN). Soft tissue sarcoma (Version 1.2026). 2026. Available from: https://www.nccn.org
  17. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812-822. Available from: https://doi.org/10.1016/s1470-2045(17)30334-0
  18. Goy BW, Syed S, Padmanabhan A, Burchette RJ, Helmstedter CS. The role of ifosfamide-doxorubicin chemotherapy in histology-specific, high-grade, locally advanced soft tissue sarcoma: a 14-year experience. Radiother Oncol. 2021;165:174-178. Available from: https://doi.org/10.1016/j.radonc.2021.10.019

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?